nodes	percent_of_prediction	percent_of_DWPC	metapath
Loteprednol—NR3C1—urine—urinary bladder cancer	0.243	0.317	CbGeAlD
Loteprednol—NR3C1—prostate gland—urinary bladder cancer	0.0873	0.114	CbGeAlD
Loteprednol—NR3C1—seminal vesicle—urinary bladder cancer	0.0738	0.0963	CbGeAlD
Loteprednol—NR3C1—epithelium—urinary bladder cancer	0.0642	0.0837	CbGeAlD
Loteprednol—NR3C1—smooth muscle tissue—urinary bladder cancer	0.0618	0.0806	CbGeAlD
Loteprednol—NR3C1—renal system—urinary bladder cancer	0.0595	0.0776	CbGeAlD
Loteprednol—NR3C1—urethra—urinary bladder cancer	0.0585	0.0762	CbGeAlD
Loteprednol—NR3C1—female reproductive system—urinary bladder cancer	0.0477	0.0622	CbGeAlD
Loteprednol—NR3C1—vagina—urinary bladder cancer	0.0431	0.0562	CbGeAlD
Loteprednol—NR3C1—lymph node—urinary bladder cancer	0.0279	0.0364	CbGeAlD
Loteprednol—NR3C1—Endoderm Differentiation—BPTF—urinary bladder cancer	0.025	0.113	CbGpPWpGaD
Loteprednol—NR3C1—Signaling events mediated by HDAC Class II—HDAC4—urinary bladder cancer	0.0165	0.0745	CbGpPWpGaD
Loteprednol—NR3C1—Glucocorticoid receptor regulatory network—KRT5—urinary bladder cancer	0.0113	0.051	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—MT2A—urinary bladder cancer	0.00954	0.043	CbGpPWpGaD
Loteprednol—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.0081	0.0365	CbGpPWpGaD
Loteprednol—NR3C1—Nuclear Receptors—ESR2—urinary bladder cancer	0.00802	0.0361	CbGpPWpGaD
Loteprednol—NR3C1—Transcription factor regulation in adipogenesis—PPARG—urinary bladder cancer	0.00687	0.031	CbGpPWpGaD
Loteprednol—NR3C1—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00634	0.0286	CbGpPWpGaD
Loteprednol—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—urinary bladder cancer	0.00632	0.0285	CbGpPWpGaD
Loteprednol—Fluoxymesterone—ESR1—urinary bladder cancer	0.00548	0.478	CrCbGaD
Loteprednol—NR3C1—Nuclear Receptors—ESR1—urinary bladder cancer	0.00486	0.0219	CbGpPWpGaD
Loteprednol—NR3C1—Signaling events mediated by HDAC Class II—ESR1—urinary bladder cancer	0.00486	0.0219	CbGpPWpGaD
Loteprednol—NR3C1—Circadian Clock—NCOR1—urinary bladder cancer	0.00461	0.0208	CbGpPWpGaD
Loteprednol—NR3C1—Nuclear Receptors—PPARG—urinary bladder cancer	0.00444	0.02	CbGpPWpGaD
Loteprednol—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—urinary bladder cancer	0.00435	0.0196	CbGpPWpGaD
Loteprednol—NR3C1—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00384	0.0173	CbGpPWpGaD
Loteprednol—NR3C1—Transcription factor regulation in adipogenesis—TNF—urinary bladder cancer	0.00365	0.0164	CbGpPWpGaD
Loteprednol—NR3C1—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00351	0.0158	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.00338	0.0152	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.00327	0.0147	CbGpPWpGaD
Loteprednol—NR3C1—Circadian Clock—CREBBP—urinary bladder cancer	0.00317	0.0143	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—PLAU—urinary bladder cancer	0.00317	0.0143	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—ESR1—urinary bladder cancer	0.00298	0.0134	CbGpPWpGaD
Loteprednol—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—urinary bladder cancer	0.00297	0.0134	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.00267	0.012	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.00265	0.012	CbGpPWpGaD
Loteprednol—Triamcinolone—PTGS2—urinary bladder cancer	0.0026	0.227	CrCbGaD
Loteprednol—NR3C1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00259	0.0117	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.00233	0.0105	CbGpPWpGaD
Loteprednol—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	0.00231	0.0104	CbGpPWpGaD
Loteprednol—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	0.0023	0.0104	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.00229	0.0103	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.00222	0.01	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.00216	0.00975	CbGpPWpGaD
Loteprednol—NR3C1—Circadian Clock—EP300—urinary bladder cancer	0.00216	0.00973	CbGpPWpGaD
Loteprednol—Betamethasone—PTGS2—urinary bladder cancer	0.00213	0.186	CrCbGaD
Loteprednol—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.00208	0.00936	CbGpPWpGaD
Loteprednol—NR3C1—Adipogenesis—FAS—urinary bladder cancer	0.00207	0.00935	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	0.00198	0.00894	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.00193	0.00872	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.00188	0.00846	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.00187	0.00842	CbGpPWpGaD
Loteprednol—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	0.00183	0.00825	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	0.00178	0.00803	CbGpPWpGaD
Loteprednol—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	0.00175	0.00788	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.00166	0.0075	CbGpPWpGaD
Loteprednol—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	0.00166	0.00748	CbGpPWpGaD
Loteprednol—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	0.00165	0.00743	CbGpPWpGaD
Loteprednol—NR3C1—Adipogenesis—RB1—urinary bladder cancer	0.00159	0.00715	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.00158	0.00714	CbGpPWpGaD
Loteprednol—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	0.00157	0.00709	CbGpPWpGaD
Loteprednol—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	0.00157	0.00707	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	0.00155	0.00699	CbGpPWpGaD
Loteprednol—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.00138	0.00622	CbGpPWpGaD
Loteprednol—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.00138	0.00621	CbGpPWpGaD
Loteprednol—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	0.00127	0.00574	CbGpPWpGaD
Loteprednol—Dexamethasone—PTGS2—urinary bladder cancer	0.00124	0.108	CrCbGaD
Loteprednol—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	0.00114	0.00514	CbGpPWpGaD
Loteprednol—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	0.00112	0.00506	CbGpPWpGaD
Loteprednol—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.00109	0.00493	CbGpPWpGaD
Loteprednol—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.00109	0.00493	CbGpPWpGaD
Loteprednol—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000938	0.00423	CbGpPWpGaD
Loteprednol—NR3C1—Adipogenesis—TNF—urinary bladder cancer	0.000881	0.00397	CbGpPWpGaD
Loteprednol—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000845	0.00381	CbGpPWpGaD
Loteprednol—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000761	0.00343	CbGpPWpGaD
Loteprednol—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000664	0.00299	CbGpPWpGaD
Loteprednol—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000606	0.00273	CbGpPWpGaD
Loteprednol—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	0.000605	0.00273	CbGpPWpGaD
Loteprednol—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000582	0.00262	CbGpPWpGaD
Loteprednol—NR3C1—Gene Expression—ESR2—urinary bladder cancer	0.000527	0.00238	CbGpPWpGaD
Loteprednol—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	0.000407	0.00183	CbGpPWpGaD
Loteprednol—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	0.000382	0.00172	CbGpPWpGaD
Loteprednol—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000345	0.00156	CbGpPWpGaD
Loteprednol—NR3C1—Gene Expression—ESR1—urinary bladder cancer	0.00032	0.00144	CbGpPWpGaD
Loteprednol—NR3C1—Gene Expression—PPARG—urinary bladder cancer	0.000292	0.00131	CbGpPWpGaD
Loteprednol—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	0.00028	0.00126	CbGpPWpGaD
Loteprednol—NR3C1—Gene Expression—MYC—urinary bladder cancer	0.000166	0.000749	CbGpPWpGaD
